Centiva Capital, LP Bio N Tech Se Call Options Transaction History

Centiva Capital, LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	SELL	$102.58 - $129.66 $1.16 Million - $1.47 Million	-11,300 Reduced 60.11%	7,500 $809,000
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $2.71 Million - $3.4 Million	-22,100 Reduced 54.03%	18,800 $2.34 Million
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $71,058 - $111,630	600 Added 1.49%	40,900 $6.14 Million
Q3 2022 Nov 14, 2022	BUY	$127.65 - $183.11 $472,305 - $677,507	3,700 Added 10.11%	40,300 $5.44 Million
Q2 2022 Aug 17, 2022	BUY	$123.25 - $186.24 $4.44 Million - $6.7 Million	36,000 Added 6000.0%	36,600 $5.46 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $239,875 - $440,515	-1,900 Reduced 76.0%	600 $102,000
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $476,607 - $797,544	2,200 Added 733.33%	2,500 $645,000
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $61,779 - $134,169	300 New	300 $82,000

357

38.4M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $25.8B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.